137 related articles for article (PubMed ID: 21385924)
21. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
22. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
23. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR
Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814
[TBL] [Abstract][Full Text] [Related]
24. Local delivery of poxvirus vaccines for melanoma.
Hörig H; Kaufman HL
Semin Cancer Biol; 2003 Dec; 13(6):417-22. PubMed ID: 15001160
[TBL] [Abstract][Full Text] [Related]
25. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study.
Mordoh J; Kairiyama C; Bover L; Solarolo E
Medicina (B Aires); 1997; 57(4):421-7. PubMed ID: 9674264
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
29. Idiosyncrasies of scalp melanoma.
Rigual NR; Cheney RT; Iwenofu OH; Li Q; Loree TR; Popat SR; Merzianu M
Laryngoscope; 2007 Aug; 117(8):1354-8. PubMed ID: 17592396
[TBL] [Abstract][Full Text] [Related]
30. The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.
Oosterhoff D; Sluijter BJ; Hangalapura BN; de Gruijl TD
Curr Top Microbiol Immunol; 2012; 351():181-220. PubMed ID: 21681685
[TBL] [Abstract][Full Text] [Related]
31. The new melanoma markers: MART-1 and Melan-A (the NIH experience).
Fetsch PA; Marincola FM; Abati A
Am J Surg Pathol; 1999 May; 23(5):607-10. PubMed ID: 10328095
[No Abstract] [Full Text] [Related]
32. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol KF; van den Bosch T; Schreibelt G; Mensink HW; Keunen JE; Kiliç E; Japing WJ; Geul KW; Westdorp H; Boudewijns S; Croockewit SA; van Rossum MM; de Goede AL; Naus NC; van der Graaf WT; Gerritsen WR; de Klein A; Punt CJ; Figdor CG; Cohen VM; Paridaens D; de Vries IJ
Ophthalmology; 2016 Oct; 123(10):2265-7. PubMed ID: 27476772
[No Abstract] [Full Text] [Related]
33. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger SM; Dummer R; Baumgaertner P; Mihic-Probst D; Schwarz K; Hammann-Haenni A; Willers J; Geldhof C; Prior JO; Kündig TM; Michielin O; Bachmann MF; Speiser DE
Eur J Immunol; 2012 Nov; 42(11):3049-61. PubMed ID: 22806397
[TBL] [Abstract][Full Text] [Related]
34. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.
Manley CA; Leibman NF; Wolchok JD; Rivière IC; Bartido S; Craft DM; Bergman PJ
J Vet Intern Med; 2011; 25(1):94-9. PubMed ID: 21143299
[TBL] [Abstract][Full Text] [Related]
35. New treatments for melanoma.
Demierre MF; Allten S; Brown R
Dermatol Nurs; 2005 Aug; 17(4):287-95. PubMed ID: 16206683
[No Abstract] [Full Text] [Related]
36. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
Fishman P; Merimski O; Baharav E; Shoenfeld Y
Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
[TBL] [Abstract][Full Text] [Related]
37. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
[TBL] [Abstract][Full Text] [Related]
38. Therapy for metastatic melanoma: an overview and update.
Boyle GM
Expert Rev Anticancer Ther; 2011 May; 11(5):725-37. PubMed ID: 21554048
[TBL] [Abstract][Full Text] [Related]
39. Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.
Letsch A; Keilholz U; Fluck M; Nagorsen D; Asemissen AM; Schmittel A; Thiel E; Scheibenbogen C
Int J Cancer; 2005 May; 114(6):936-41. PubMed ID: 15645483
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.
Kaufman HL; DeRaffele G; Divito J; Hörig H; Lee D; Panicali D; Voulo M
Hum Gene Ther; 2001 Jul; 12(11):1459-80. PubMed ID: 11485637
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
